JP2023521227A5 - - Google Patents

Info

Publication number
JP2023521227A5
JP2023521227A5 JP2022562594A JP2022562594A JP2023521227A5 JP 2023521227 A5 JP2023521227 A5 JP 2023521227A5 JP 2022562594 A JP2022562594 A JP 2022562594A JP 2022562594 A JP2022562594 A JP 2022562594A JP 2023521227 A5 JP2023521227 A5 JP 2023521227A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cancer
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521227A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/059376 external-priority patent/WO2021209356A1/en
Publication of JP2023521227A publication Critical patent/JP2023521227A/ja
Publication of JP2023521227A5 publication Critical patent/JP2023521227A5/ja
Pending legal-status Critical Current

Links

JP2022562594A 2020-04-14 2021-04-12 癌の併用療法 Pending JP2023521227A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063009565P 2020-04-14 2020-04-14
US63/009,565 2020-04-14
US202063110101P 2020-11-05 2020-11-05
US63/110,101 2020-11-05
PCT/EP2021/059376 WO2021209356A1 (en) 2020-04-14 2021-04-12 Combination treatment for cancer

Publications (2)

Publication Number Publication Date
JP2023521227A JP2023521227A (ja) 2023-05-23
JP2023521227A5 true JP2023521227A5 (cg-RX-API-DMAC7.html) 2024-04-23

Family

ID=75497923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562594A Pending JP2023521227A (ja) 2020-04-14 2021-04-12 癌の併用療法

Country Status (7)

Country Link
US (1) US20230131598A1 (cg-RX-API-DMAC7.html)
EP (1) EP4136112A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023521227A (cg-RX-API-DMAC7.html)
CN (1) CN115397861A (cg-RX-API-DMAC7.html)
AU (1) AU2021257570A1 (cg-RX-API-DMAC7.html)
CA (1) CA3171597A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021209356A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
WO2024030956A2 (en) * 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
KR102023661B1 (ko) 2011-03-31 2019-09-23 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Icos에 대한 항체 및 이의 용도
ES2684552T3 (es) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
HRP20251424T1 (hr) * 2016-08-30 2025-12-19 Xencor, Inc. Bispecifična imunomodulacijska protutijela koja se vežu na kostimulacijske receptore i receptore imunosnih kontrolnih točaka
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3559041A1 (en) * 2016-12-20 2019-10-30 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
WO2018115859A1 (en) * 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
AU2018205401B2 (en) 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
US20200024351A1 (en) * 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TWI791519B (zh) * 2017-04-27 2023-02-11 美商提薩羅有限公司 針對淋巴細胞活化基因-3(lag-3)之抗體藥劑及其用途
CA3066778A1 (en) * 2017-06-21 2018-12-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules

Similar Documents

Publication Publication Date Title
JP7122357B2 (ja) がんの治療のための方法、組成物、及びキット
US20210040216A1 (en) Methods of treating her2-positive cancer
CN109153723B (zh) 抗pd-1抗体与放射的组合治疗癌症
CA2549652C (en) Cd40 antibody formulation and methods
CN105263520B (zh) 包含抗cd38抗体和来那度胺的组合物
CN114746117B (zh) 抗dll3药剂的给药方案
JP2021523122A5 (cg-RX-API-DMAC7.html)
JP2023502585A (ja) 癌の治療のための、PD-1、TGFβ、及びTIGITの組み合わせ阻害
WO2013138371A1 (en) Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
JP2022513062A5 (cg-RX-API-DMAC7.html)
JP2022535062A (ja) Gm-csf拮抗薬を用いたがんの治療
JP2022184998A (ja) 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ
WO2021209356A1 (en) Combination treatment for cancer
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
AU2021269832B2 (en) Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
JP2023521228A5 (cg-RX-API-DMAC7.html)
CA3212604A1 (en) Methods for treating cancer with anti-ilt3 antibodies
JP2019014724A (ja) 併用療法
US10689459B2 (en) Treatment of breast cancer brain metastases
Li et al. Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody®) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumors
WO2025256641A1 (zh) 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤
TW202517679A (zh) 以抗ilt2抗體治療癌症
HK40101387A (en) Use of the combination of anti-her2 antibodies and chemotherapeutic agent for treatment of gastric cancer
JP2025524957A (ja) 抗GARP-TGF-β1/PD-1併用療法
HK40101387B (en) Use of the combination of anti-her2 antibodies and chemotherapeutic agent for treatment of gastric cancer